Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics logo
GBX 0.46 0.00 (0.00%)
As of 11/20/2026 11:58 AM Eastern

IDHC vs. AGL, PRM, GENI, MXCT, and DMTR

Should you buy Integrated Diagnostics stock or one of its competitors? Integrated Diagnostics's main competitors and comparable companies include ANGLE (AGL), Proteome Sciences (PRM), GENinCode (GENI), MaxCyte (MXCT), and Deepmatter Group (DMTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Integrated Diagnostics compare to ANGLE?

ANGLE (LON:AGL) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Integrated Diagnostics has higher revenue and earnings than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ANGLE£2.62M2.89-£21.76M-£4.80N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

ANGLE has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.442, meaning that its share price is 56% less volatile than the broader market.

In the previous week, ANGLE's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
ANGLE Neutral
Integrated Diagnostics Neutral

Integrated Diagnostics has a net margin of 16.49% compared to ANGLE's net margin of -1,560.86%. Integrated Diagnostics' return on equity of 39.61% beat ANGLE's return on equity.

Company Net Margins Return on Equity Return on Assets
ANGLE-1,560.86% -157.49% -29.89%
Integrated Diagnostics 16.49%39.61%9.69%

17.5% of ANGLE shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 2.7% of ANGLE shares are held by company insiders. Comparatively, 81.1% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Integrated Diagnostics beats ANGLE on 9 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to Proteome Sciences?

Proteome Sciences (LON:PRM) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Proteome Sciences has a beta of 0.157, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.442, suggesting that its stock price is 56% less volatile than the broader market.

0.0% of Proteome Sciences shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 36.7% of Proteome Sciences shares are owned by insiders. Comparatively, 81.1% of Integrated Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Integrated Diagnostics has a net margin of 16.49% compared to Proteome Sciences' net margin of -61.46%. Integrated Diagnostics' return on equity of 39.61% beat Proteome Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Proteome Sciences-61.46% 23.85% -19.25%
Integrated Diagnostics 16.49%39.61%9.69%

Integrated Diagnostics has higher revenue and earnings than Proteome Sciences. Proteome Sciences is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Proteome Sciences£3.77M0.97-£4.08M-£0.72N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

In the previous week, Proteome Sciences' average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
Proteome Sciences Neutral
Integrated Diagnostics Neutral

Summary

Integrated Diagnostics beats Proteome Sciences on 10 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to GENinCode?

Integrated Diagnostics (LON:IDHC) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

7.7% of Integrated Diagnostics shares are held by institutional investors. Comparatively, 2.8% of GENinCode shares are held by institutional investors. 81.1% of Integrated Diagnostics shares are held by insiders. Comparatively, 8.4% of GENinCode shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Integrated Diagnostics has higher revenue and earnings than GENinCode. GENinCode is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00
GENinCode£2.60M1.62-£6.10M-£1.27N/A

Integrated Diagnostics has a net margin of 16.49% compared to GENinCode's net margin of -202.42%. Integrated Diagnostics' return on equity of 39.61% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics16.49% 39.61% 9.69%
GENinCode -202.42%-481.34%-63.99%

In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled GENinCode'saverage media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
GENinCode Neutral

Integrated Diagnostics has a beta of 0.442, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

Summary

Integrated Diagnostics beats GENinCode on 9 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to MaxCyte?

MaxCyte (LON:MXCT) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Integrated Diagnostics has a net margin of 16.49% compared to MaxCyte's net margin of -106.29%. Integrated Diagnostics' return on equity of 39.61% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-106.29% -18.73% -11.07%
Integrated Diagnostics 16.49%39.61%9.69%

24.0% of MaxCyte shares are held by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are held by institutional investors. 1.9% of MaxCyte shares are held by insiders. Comparatively, 81.1% of Integrated Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, MaxCyte's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
MaxCyte Neutral
Integrated Diagnostics Neutral

Integrated Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.04-£45.08M-£40.00N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.442, indicating that its stock price is 56% less volatile than the broader market.

Summary

Integrated Diagnostics beats MaxCyte on 8 of the 11 factors compared between the two stocks.

How does Integrated Diagnostics compare to Deepmatter Group?

Integrated Diagnostics (LON:IDHC) and Deepmatter Group (LON:DMTR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Integrated Diagnostics has higher revenue and earnings than Deepmatter Group. Deepmatter Group is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00
Deepmatter Group£1.04M0.00N/A-£0.30N/A

7.7% of Integrated Diagnostics shares are owned by institutional investors. 81.1% of Integrated Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Integrated Diagnostics has a net margin of 16.49% compared to Deepmatter Group's net margin of 0.00%. Integrated Diagnostics' return on equity of 39.61% beat Deepmatter Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Integrated Diagnostics16.49% 39.61% 9.69%
Deepmatter Group N/A N/A N/A

In the previous week, Integrated Diagnostics' average media sentiment score of 0.00 equaled Deepmatter Group'saverage media sentiment score.

Company Overall Sentiment
Integrated Diagnostics Neutral
Deepmatter Group Neutral

Summary

Integrated Diagnostics beats Deepmatter Group on 8 of the 8 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDHC vs. The Competition

MetricIntegrated DiagnosticsLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£2.69M£10.69B£7.78B£2.67B
Dividend Yield1.84%1.46%2.47%5.11%
P/E Ratio0.0049.0032.9322.78
Price / Sales0.008.468.104.91
Price / CashN/A26.5521.0120.23
Price / Book0.004.194.262.40
Net Income£4.01T£56.66B£3.50B£5.88B
1 Month Performance-7.60%-7.81%-10.48%-4.75%
1 Year Performance-31.56%11.09%-4.61%5.15%

Integrated Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDHC
Integrated Diagnostics
N/AGBX 0.46
flat
N/A-30.0%£2.69M£9.17B0.006,692
AGL
ANGLE
N/AGBX 2.35
-11.3%
N/A+0.0%£7.58M£2.62MN/A650
PRM
Proteome Sciences
N/AGBX 1.69
+16.2%
N/A-24.0%£5.93M£3.77MN/A240
GENI
GENinCode
N/AGBX 0.56
-6.7%
N/A-75.7%£4.22M£2.60MN/A2,300
MXCT
MaxCyte
N/AGBX 1.26
-3.8%
N/A-31.6%£1.34M£32.29MN/A80

Related Companies and Tools


This page (LON:IDHC) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners